Pasireotide

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Cushing's Disease

Conditions

Cushing's Disease

Trial Timeline

Dec 1, 2006 → May 1, 2014

NCT ID

NCT00434148

About Pasireotide

Pasireotide is a phase 3 stage product being developed by Novartis for Cushing's Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT00434148. Target conditions include Cushing's Disease.

What happened to similar drugs?

2 of 9 similar drugs in Cushing's Disease were approved

Approved (2) Terminated (1) Active (6)

✅Pasireotide s.c. + Sitagliptin + Liraglutide + Insulin + Pasireotide LAR + MetforminNovartisApproved

✅Pasireotide + Cabergoline + Pasireotide LARRecordatiApproved

🔄pasireotide LAR + SOM230 LAR 30 mg + SOM230 LAR 10 mgNovartisPhase 3

🔄Pasireotide sub-cutaneousNovartisPhase 3

🔄osilodrostat + osilodrostat PlaceboNovartisPhase 3

🔄mifepristoneCorcept TherapeuticsPhase 3

🔄MifepristoneCorcept TherapeuticsPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (8)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03103009	Phase 1	Completed	Mar 22, 2017	Dec 22, 2017	Hyperinsulinemic Hypoglycemia
NCT02780882	Phase 2	Withdrawn	Dec 1, 2015	Jun 1, 2019	Ectopic ACTH Syndrome
NCT01617733	Phase 2	Terminated	Mar 1, 2011	Dec 1, 2015	Nelson Syndrome
NCT00698464	Phase 1	Completed	Jul 1, 2008	—	Hepatic Cirrhosis
NCT00434148	Phase 3	Completed	Dec 1, 2006	May 1, 2014	Cushing's Disease
NCT00446082	Phase 1	Completed	Jun 1, 2006	Nov 1, 2013	Carcinoid Tumor
NCT00171730	Phase 2	Completed	Aug 24, 2004	Dec 6, 2013	Acromegaly
NCT00171951	Phase 2	Completed	Aug 13, 2004	Jul 8, 2013	Cushing Disease

Competing Products

18 competing products in Cushing's Disease

See all competitors

Product	Company	Stage	Hype Score
AZD4017 and prednisolone + Placebo Oral Tablet and prednisolone	AstraZeneca	Phase 2	35
pasireotide LAR + SOM230 LAR 30 mg + SOM230 LAR 10 mg	Novartis	Phase 3	40
Pasireotide sub-cutaneous	Novartis	Phase 3	40
osilodrostat + osilodrostat Placebo	Novartis	Phase 3	40
Osilodrostat	Novartis	Phase 2	35
Pasireotide s.c. + Sitagliptin + Liraglutide + Insulin + Pasireotide LAR + Metformin	Novartis	Approved	43
SOM230 s.c.	Novartis	Phase 2	35
Lu AG13909	Lundbeck	Phase 2	39
Osilodrostat	Recordati	Pre-clinical	23
Pasireotide + Cabergoline + Pasireotide LAR	Recordati	Approved	40
osilodrostat	Recordati	Phase 2	32
Osilodrostat	Recordati	Pre-clinical	27
mifepristone	Corcept Therapeutics	Phase 3	37
CORT125134	Corcept Therapeutics	Phase 2	32
Cushing's syndrome confirmation	Corcept Therapeutics	Pre-clinical	15
Mifepristone	Corcept Therapeutics	Phase 3	37
mifepristone	Corcept Therapeutics	Phase 3	37
mifepristone	Corcept Therapeutics	Phase 3	29